NASDAQ : STRO
Sutro Biopharma, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 9.1 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 150.89M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 151.05M |
| Enterprise Value | -2.51M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 16.58M |
| Shares Outstanding | 16.58M |
| Shares Change (YoY) | +38.81% |
| Shares Change (QoQ) | +26.67% |
| Owned by Insiders (%) | 0.92% |
| Owned by Institutions (%) | 65.85% |
| Float | 10.76M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.31 |
| Forward PS | 3.74 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.32 |
| Quick Ratio | 3.22 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.17 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -36.08% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -93.14% |
| Weighted Average Cost of Capital (WACC) | 31.94% |
| Revenue Per Employee | $357,047 |
| Profits Per Employee | -$1.41M |
| Employee Count | 128 |
| Asset Turnover | 0.20 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -96,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.50 |
| 52-Week Price Change | -18.66% |
| 50-Day Moving Average | 15.15 |
| 200-Day Moving Average | 23.01 |
| Relative Strength Index (RSI) | 25.29 |
| Average Volume (20 Days) | 347,161 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.96M |
| Short Previous Month | 1.85M |
| Short % of Shares Out | 11.83% |
| Short % of Float | 18.22% |
| Short Ratio (days to cover) | 5.66 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 45.70M |
| Gross Profit | -99.04M |
| Operating Income | -131.86M |
| Pretax Income | -180.73M |
| Net Income | -180.64M |
| EBITDA | -125.80M |
| EBIT | -131.86M |
| Loss Per Share | -$15.47 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 164.35M |
| Total Debt | 10.78M |
| Net Cash | 153.56M |
| Net Cash Per Share | $9.26 |
| Equity (Book Value) | -103.32M |
| Book Value Per Share | -6.23 |
| Working Capital | 122.75M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -145.17M |
| Capital Expenditures | -446,000 |
| Depreciation & Amortization | 6.06M |
| Net Borrowing | n/a |
| Free Cash Flow | -145.62M |
| FCF Per Share | -$8.78 |
Margins
| Measure | Value |
|---|
| Gross Margin | -216.71% |
| Operating Margin | -288.52% |
| Pretax Margin | -395.46% |
| Profit Margin | n/a |
| EBITDA Margin | -275.25% |
| EBIT Margin | -288.52% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -38.81% |
| Shareholder Yield | -38.81% |
| Earnings Yield | -169.84% |
| FCF Yield | -96.40% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $47.23 |
| Price Target Difference | 418.44% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | -34.63% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Dec 3, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -8.38 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |